PBA
TNGX icon

Paradigm Biocapital Advisors’s Tango Therapeutics TNGX Stock Holding History

Paradigm Biocapital Advisors’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$199M Buy
6,357,523
+2,347,844
+59% +$58M 3.72% 8
2026
Q1 		$83.9M Buy
+4,009,679
New +$55.8M 1.71% 19
2025
Q4 		– Sell
-3,086,184
Closed -$25.9M – 43
2025
Q3 		$25.9M Buy
+3,086,184
New +$20.9M 0.74% 29

Other funds holding TNGX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Paradigm Biocapital Advisors's TNGX Position: Q2 2026 in Review

Paradigm Biocapital Advisors increased its Tango Therapeutics (TNGX) stake by 59% in Q2 2026, buying an estimated $58M and bringing the position to 6,357,523 shares worth $199M. The position accounts for 3.72% of the portfolio, ranked #8.

Paradigm Biocapital Advisors first reported a position in TNGX in Q3 2025 and has held it in 3 quarters since. 249 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

  • Paradigm Biocapital Advisors held 6,357,523 shares of Tango Therapeutics worth $199M as of Q2 2026.
  • Paradigm Biocapital Advisors bought 2,347,844 Tango Therapeutics shares in Q2 2026, an estimated $58M.
  • Tango Therapeutics made up 3.72% of Paradigm Biocapital Advisors's portfolio in Q2 2026, its #8 holding.
  • Paradigm Biocapital Advisors first reported a position in Tango Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 249 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on Paradigm Biocapital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.